Nicox to Present Key Data at AGS Annual Meeting 2026

Nicox SA, a prominent player in ophthalmology, will reveal phase 3 study outcomes at the American Glaucoma Society (AGS) Annual Meeting 2026. The event will occur from February 19-22 in Rancho Mirage, California. The data focus on NCX 470, a nitric oxide-donating bimatoprost aimed at treating open-angle glaucoma and ocular hypertension.

Two podium presentations are scheduled, detailing findings from the DENALI Trial and a phase 3b clinical trial on aqueous humor dynamics. Dr. S. Asrani and Dr. A. Sit will deliver these insights on February 20. A poster presentation by Dr. J. Bacharach will further explore the US subgroup of the DENALI Trial.

These presentations signal progress as Nicox prepares regulatory submissions for NCX 470 in the U.S. and China.